Dr. Darrah is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8700 Beverly Blvd
Los Angeles, CA 90048Phone+1 310-423-1160Fax+1 310-423-4646
Summary
- Dr. Justin M. Darrah specializes in hematology, stem cell/bone marrow transplant, and CAR T-cell therapy, and is the director of the CAR T-cell therapy program. His specific focus is in the treatment of lymphoma, as well as leukemia and multiple myeloma. He has over 10 years of experience and is board certified in Internal Medicine, Hematology, and Medical Oncology. He practices at the Samuel Oschin Comprehensive Cancer Institute located at Cedars-Sinai Medical Center.
Education & Training
Los Angeles County-Harbor-UCLA Medical Center 1Fellowship, Hematology and Medical Oncology, 2016 - 2018
Temple University HospitalChief Residency, Internal Medicine, 2015 - 2016- Temple University HospitalResidency, Internal Medicine, 2011 - 2014
Lewis Katz School of Medicine at Temple UniversityClass of 2011
City of Hope National Medical CenterFellowship, Blood & Bone Marrow Transplant
Certifications & Licensure
CA State Medical License 2015 - 2025
PA State Medical License 2011 - 2016- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Start of enrollment: 2021 Nov 12
Roles: Principal Investigator
- Fludarabine and Total Body Irradiation 800 Centigray (cGy) or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil Start of enrollment: 2022 Apr 26
- First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma Start of enrollment: 2018 Jun 26
- Join now to see all
Publications & Presentations
PubMed
- 24 citationsAutologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma.Reid W. Merryman, Robert A. Redd, Taiga Nishihori, Julio C. Chavez, Yago Nieto
Blood Advances. 2021-03-23 - 33 citationsLongitudinal SARS-CoV-2 mRNA vaccine-induced humoral immune responses in cancer patients.Jane C. Figueiredo, Noah Merin, Omid Hamid, So Yung Choi, Tucker Lemos
Cancer Research. 2021-11-10 - 54 citationsHaematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative studyMohamed A. Kharfan-Dabaja, Monzr M. Al Malki, Uday Deotare, Renju V. Raj, Najla El-Jurdi
British Journal of Haematology. 2017-12-01
Abstracts/Posters
- Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, a...Justin Darrah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin LymphomaJustin Darrah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
Hitting Stem Cell and CAR T TargetsJanuary 17th, 2023- December Research HighlightsDecember 29th, 2022
- A Leading-Edge Lymphoma ProgramDecember 21st, 2022
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
